AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix’s naïve library technology enables rapid antibody discovery with high diversity (up to 10¹⁰ variants) while eliminating the need for animal immunization. Compared to hybridoma technology, our phage display approach reduces turnaround time to 3-4 months and removes the need for further humanization, ensuring efficient and cost-effective therapeutic antibody development.
Rapid Antibody Screening
Select high-affinity antibodies within 3-4 months, twice as fast
Animal-Free & Ethical
No animal immunization, fully human naïve library screening
No Further Humanization Needed
Direct selection of fully human antibodies, reducing costs
| Library | Format | Species | Size（Capacity） |
|---|---|---|---|
| LiAb-SFCOVID-19™ | scFv | Human – COVID-19 recovered donors | 1.35 × 10¹⁰ |
| LiAb-SFMAX™ | scFv | Human – 5 ethnic groups, 368 donors | 7.38 × 10¹⁰ |
| LiAb-SFAutoimmune™ | scFv | Human – with autoimmune disease | 4.78 × 10⁹ |
| LiAb-VHHMAX™ | VHH | Camel, llama, alpaca ， 76 donors | 2.71 × 10¹⁰ |
| LiAb-SFDab™ | scFv | Dog – 6 breeds，26 donors | 1.52 × 10¹⁰ |
| LiAb-SFCab™ | scFv | Cat – 10 breeds，78 donors | 1.67 × 10¹⁰ |
| LiAb-SFRab™ | scFv | Rabbit– 5 breeds，64 donors | 2.95 × 10¹⁰ |
| LiPep-12 | Peptide 12-mer | / | 1.00 × 10⁹ |
| LiPep-7 | Peptide 7-mer | / | 1.00 × 10⁹ |
Example of the panning (biopanning) protocol in Phage Display.
Explore real-world yeast protein expression case studies from AtaGenix. Our Pichia pastoris and Saccharomyces cerevisiae platforms deliver high-yield recombinant proteins with proper folding and glycosylation — supporting enzyme production, diagnostic antigen development, and antibody screening applications.
A 2021 Small Methods study used dual phage display libraries — an overlapping spike peptide library for epitope mapping and a 8.7×10⁹ patient-derived ScFv library for antibody discovery — to identify three immunodominant RBM epitopes (S431–454, S470–486, S501–515) and isolate human neutralizing monoclonal antibodies from COVID-19 patients. S470–486 emerged as the key protective epitope (diagnostic AUC ~1.0; mouse immunization produced neutralizing antibodies). AtaGenix provided phage library construction, biopanning screening, and antibody expression services that enabled the 10⁹-scale discovery campaign. DOI: 10.1002/smtd.202100058.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
